In this episode, VibeCast host Ray Dogum speaks with Sandra Shpilberg, Co-founder and CEO of Adnexi, about using AI to develop effective strategies for biopharma key expert and digital opinion leader selection to elevate your product launch.
The Importance of Collaboration in Drug Development
In the pharmaceutical industry, collaboration plays a crucial role in driving innovation and advancing drug development processes. It is widely acknowledged that the complexity of developing new drugs requires a collective effort from various stakeholders across geographies and functions. Collaboration fosters a diverse range of expertise, perspectives, and resources coming together to tackle the challenges inherent in drug development. This ensures a more holistic approach that can lead to groundbreaking discoveries and improved healthcare outcomes. Sandra Shpilberg’s insights during the VibeCast episode shed light on the paramount importance of finding the best key opinion leaders, influencers, and digital opinion leaders in drug development. By likening drug development to raising a child and emphasizing the necessity of a ‘planet’ to achieve success, Sandra highlighted the interconnected nature of this industry. Her views underscored the critical need for companies, individuals, and countries to join forces and leverage their strengths through collaboration, transcending boundaries for the greater good of advancing healthcare globally.
Key moments:
- 00:00:00 – Introducing Sandra Shpilberg
- 00:01:45 – Transitioning into Biopharma
- 00:06:06 – Starting Adnexi
- 00:10:29 – Importance of Finding Key Opinion Leaders
- 00:14:08 – Understanding Key Opinion Leaders
- 00:15:22 – Identifying Key Opinion Leaders
- 00:18:20 – Traditional Approach to Finding Experts
- 00:23:15 – Pros and Cons of Digital Opinion Leaders
- 00:26:03 – Adnexi’s Unique Approach
- 00:29:17 – Effective Social Media Platforms
- 00:30:52 – Impact of Demographics on Platform Selection
- 00:32:33 – Changes in Biotech Funding Environment
- 00:33:59 – Adapting to Market Changes
- 00:35:35 – Global Reach
- 00:36:20 – Conclusion
Guest Bio
Sandra Shpilberg is the CEO & co-founder of Adnexi, a software platform that helps biopharma identify Key Opinion Leaders (KOL) and Digital Opinion Leaders (DOL) and influential HCPs who can accelerate treatment development and launch. Adnexi provides rapid, accurate, tech-enabled, customized, complete and continuously updating identification of KOLs and DOLs for any disease. Before this, Sandra was the Founder and CEO of Seeker Health, a breakthrough digital patient-finding platform, which accelerated clinical trial and patient recruitment. Seeker Health grew to enroll over 60 clinical trials in 3 years. EVERSANA acquired Seeker Health in September 2018. Prior to her entrepreneurial pursuits, Sandra held executive roles at biopharmaceutical companies, including Nora Therapeutics, and BioMarin Pharmaceutical where she led the commercial launches of NAGLAZYME and KUVAN, and advanced PALINZIQ from Phase 2 to Phase 3. She’s originally from Uruguay, speaks fluent Spanish, and brings a global and diverse approach to her work and impact. She holds a BBA in Accounting from Pace University and an MBA in Marketing and Entrepreneurial Management from The Wharton School at the University of Pennsylvania.
Guest Links
- Linkedin: https://www.linkedin.com/in/sandra-shpilberg-b7b334/
- X: https://www.x.com/sandrashpilberg
- Adnexi Website: https://www.adnexi.com
